Data / Form D filings / Amytrx Therapeutics, Inc.
Amytrx Therapeutics, Inc.: Form D filings
Amytrx Therapeutics, Inc., a pharmaceuticals company in Nashville, TN, filed 6 Form D notices with the SEC between 2015 and 2024. The latest, on January 31, 2024, reports $725,000 sold of a $6 million offering to 7 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 40 Burton Hills Boulevard, Suite 200, Nashville, TN, 37215
- Phone
- (205) 427-8787
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Tennessee
- Revenue range
- No Revenues
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1649024
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jan 31, 2024 | New notice | $6,000,000 | $725,000 | $5,275,000 | 7 | Dec 15, 2023 | sec.gov |
| Aug 12, 2020 | New notice | $12,000,000 | $3,590,000 | $8,410,000 | 34 | Jan 16, 2020 | sec.gov |
| Sep 5, 2017 | New notice | $2,095,000 | $0 | $2,095,000 | 0 | Jul 17, 2017 | sec.gov |
| Jul 1, 2016 | Amendment | $4,500,000 | $600,000 | $3,900,000 | 7 | Jun 26, 2015 | sec.gov |
| Dec 16, 2015 | Amendment | $3,000,000 | $600,000 | $2,400,000 | 7 | Jun 26, 2015 | sec.gov |
| Aug 4, 2015 | New notice | $2,000,000 | $50,000 | $1,950,000 | 1 | Jun 26, 2014 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Matthew Gonda | Director | |
| Lawrence Greer | Director | |
| Satish Joshi | Director | |
| Michael Howell | Director | |
| Dennis Carlo | Director | |
| Raymond Pirtle | Director |
Every Form D from the week of Jan 29, 2024 · All recent filings in Tennessee · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Amytrx Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.